LUC00328I2 - - Google Patents

Info

Publication number
LUC00328I2
LUC00328I2 LU00328C LUC00328C LUC00328I2 LU C00328 I2 LUC00328 I2 LU C00328I2 LU 00328 C LU00328 C LU 00328C LU C00328 C LUC00328 C LU C00328C LU C00328 I2 LUC00328 I2 LU C00328I2
Authority
LU
Luxembourg
Application number
LU00328C
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52628493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00328(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of LUC00328I2 publication Critical patent/LUC00328I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Endocrinology (AREA)
LU00328C 2013-09-06 2024-01-24 LUC00328I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013184684 2013-09-06

Publications (1)

Publication Number Publication Date
LUC00328I2 true LUC00328I2 (fr) 2026-03-04

Family

ID=52628493

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00328C LUC00328I2 (fr) 2013-09-06 2024-01-24

Country Status (25)

Country Link
US (1) US9943537B2 (fr)
EP (2) EP4201424A1 (fr)
JP (2) JP6425653B2 (fr)
KR (1) KR101993963B1 (fr)
AU (1) AU2014316030C1 (fr)
CY (2) CY1126037T1 (fr)
DK (1) DK3042669T3 (fr)
ES (1) ES2946472T3 (fr)
FI (2) FI3042669T3 (fr)
FR (1) FR24C1005I1 (fr)
HR (1) HRP20230523T1 (fr)
HU (2) HUE062034T2 (fr)
LT (2) LT3042669T (fr)
LU (1) LUC00328I2 (fr)
NO (1) NO2024005I1 (fr)
PL (1) PL3042669T3 (fr)
PT (1) PT3042669T (fr)
RS (1) RS64243B1 (fr)
RU (1) RU2682161C2 (fr)
SI (1) SI3042669T1 (fr)
SM (1) SMT202300167T1 (fr)
TW (1) TWI641385B (fr)
UA (1) UA121538C2 (fr)
WO (1) WO2015034032A1 (fr)
ZA (1) ZA201602258B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014316030C1 (en) 2013-09-06 2024-08-15 Les Laboratoires Servier Antitumor agent and antitumor effect enhancer
EP3693019A1 (fr) 2016-01-08 2020-08-12 Taiho Pharmaceutical Co., Ltd. Agent antitumoral contenant un immunomodulateur
EP3442534A1 (fr) * 2016-04-13 2019-02-20 Boehringer Ingelheim International GmbH Combinaison pharmaceutique de nintédanib, de trifluridine et de tipiracil pour le traitement du cancer colorectal
EP3646887A4 (fr) * 2017-06-30 2021-03-24 Korea Advanced Institute of Science and Technology Conjugué de protéine de vegf-grab et de médicament, et son utilisation
US12691115B2 (en) 2019-05-14 2026-07-28 Marshall University Research Corporation Methods for treatment of obesity, atherosclerosis, and thrombosis
KR20220154986A (ko) 2021-05-14 2022-11-22 윤상은 휴대용 마스크끈 절단기
AR127893A1 (es) * 2021-12-10 2024-03-06 Servier Lab Terapia del cáncer dirigida a egfr
TW202339786A (zh) 2022-01-21 2023-10-16 日商中外製藥股份有限公司 癌症之治療或預防用醫藥
WO2023204259A1 (fr) 2022-04-20 2023-10-26 中外製薬株式会社 Produit pharmaceutique pour le traitement ou la prévention du cancer
WO2024177036A1 (fr) * 2023-02-20 2024-08-29 大鵬薬品工業株式会社 Préparation combinée de ftd-tpi, antagoniste de la voie pd-1 et utilisation combinée d'un antagoniste de la voie du vegf

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3088757B2 (ja) 1995-03-29 2000-09-18 大鵬薬品工業株式会社 ウラシル誘導体並びにそれを含有する抗腫瘍効果増強剤及び抗腫瘍剤
US7312243B1 (en) * 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
DK1849470T4 (en) 2005-01-26 2024-04-02 Taiho Pharmaceutical Co Ltd Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor
US7799783B2 (en) * 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
US9616081B2 (en) 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate
UA114840C2 (uk) 2013-03-27 2017-08-10 Тайхо Фармасьютікал Ко., Лтд. Протипухлинний агент, який включає гідрат гідрохлориду іринотекану
AU2014316030C1 (en) 2013-09-06 2024-08-15 Les Laboratoires Servier Antitumor agent and antitumor effect enhancer

Also Published As

Publication number Publication date
AU2014316030C1 (en) 2024-08-15
CY2024001I2 (el) 2024-09-20
WO2015034032A1 (fr) 2015-03-12
KR101993963B1 (ko) 2019-06-27
EP3042669A1 (fr) 2016-07-13
JP6425653B2 (ja) 2018-11-21
KR20160050026A (ko) 2016-05-10
RS64243B1 (sr) 2023-06-30
DK3042669T3 (da) 2023-06-12
AU2014316030B2 (en) 2019-02-28
US9943537B2 (en) 2018-04-17
HUS2400001I1 (hu) 2024-02-28
CY1126037T1 (el) 2023-11-15
LTPA2024502I1 (fr) 2024-03-12
JPWO2015034032A1 (ja) 2017-03-02
TW201536319A (zh) 2015-10-01
AU2014316030A1 (en) 2016-04-28
RU2016112421A (ru) 2017-10-11
FI3042669T3 (fi) 2023-05-25
EP4201424A1 (fr) 2023-06-28
JP2018076369A (ja) 2018-05-17
UA121538C2 (uk) 2020-06-25
HUE062034T2 (hu) 2023-09-28
RU2682161C2 (ru) 2019-03-15
TWI641385B (zh) 2018-11-21
PT3042669T (pt) 2023-06-15
HRP20230523T1 (hr) 2023-08-04
EP3042669A4 (fr) 2017-04-12
ZA201602258B (en) 2017-09-27
LT3042669T (lt) 2023-06-26
NO2024005I1 (no) 2024-01-25
FIC20240002I1 (fi) 2024-01-25
PL3042669T3 (pl) 2023-06-26
SI3042669T1 (sl) 2023-07-31
JP6557744B2 (ja) 2019-08-07
FR24C1005I1 (fr) 2024-04-19
CY2024001I1 (el) 2024-09-20
ES2946472T3 (es) 2023-07-19
EP3042669B1 (fr) 2023-03-08
US20160193241A1 (en) 2016-07-07
RU2016112421A3 (fr) 2018-06-20
SMT202300167T1 (it) 2023-07-20

Similar Documents

Publication Publication Date Title
AP2016009275A0 (fr)
BR112015007533A2 (fr)
BR102016010778A2 (fr)
BR112014017733A2 (fr)
BR112014017739A2 (fr)
BR112014018502A2 (fr)
BR112014018516A2 (fr)
BR112014017765A2 (fr)
BR112014018480A2 (fr)
BR112014017855A2 (fr)
BR112014020341A2 (fr)
BR112014018468A2 (fr)
BR112016005305A2 (fr)
LTPA2024502I1 (fr)
BR112014019204A2 (fr)
BR112016009844A2 (fr)
BR112014017901A2 (fr)
BR112014017745A2 (fr)
BR112016013484A2 (fr)
BR112014017722A2 (fr)
BR112014017653A2 (fr)
BR112014018578A2 (fr)
BR112014017601A2 (fr)
BR112015015312A2 (fr)
BR112014024039A2 (fr)